Total Payments
$890,793
2024 Payments
$184,101
Companies
20
Transactions
310
Payment Breakdown by Category
Research$853,948 (95.9%)
Consulting$32,425 (3.6%)
Other$3,750 (0.4%)
Food & Beverage$669.95 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $853,948 | 275 | 95.9% |
| Consulting Fee | $32,425 | 14 | 3.6% |
| Honoraria | $2,400 | 1 | 0.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,350 | 2 | 0.2% |
| Food and Beverage | $669.95 | 18 | 0.1% |
Payments by Type
Research
$853,948
275 transactions
General
$36,845
35 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bausch Health US, LLC | $405,161 | 23 | $0 (2021) |
| Alcon Research LLC | $202,665 | 236 | $0 (2024) |
| Amneal Pharmaceuticals LLC | $172,650 | 1 | $0 (2024) |
| Kala Pharmaceuticals, Inc. | $50,800 | 4 | $0 (2019) |
| Allergan, Inc. | $29,175 | 15 | $0 (2022) |
| Mallinckrodt Hospital Products Inc. | $5,850 | 1 | $0 (2021) |
| Carl Zeiss Meditec, Inc. | $5,000 | 2 | $0 (2018) |
| Alcon Vision LLC | $4,000 | 1 | $0 (2024) |
| ABBVIE INC. | $3,900 | 2 | $0 (2024) |
| Vertical Pharmaceuticals, LLC | $2,750 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $184,101 | 11 | Amneal Pharmaceuticals LLC ($172,650) |
| 2023 | $124.75 | 2 | Kowa Research Institute, Inc. ($100.00) |
| 2022 | $1,070 | 5 | Allergan, Inc. ($996.56) |
| 2021 | $321,851 | 24 | Bausch Health US, LLC ($311,061) |
| 2020 | $96,850 | 6 | Bausch Health US, LLC ($94,100) |
| 2019 | $253,680 | 246 | Alcon Research LLC ($198,579) |
| 2018 | $5,500 | 3 | Carl Zeiss Meditec, Inc. ($5,000) |
| 2017 | $27,616 | 13 | Allergan Inc. ($22,579) |
All Payment Transactions
310 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| 11/07/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $3,250.00 | General |
| 08/08/2024 | Alcon Vision LLC | — | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| 06/27/2024 | Amneal Pharmaceuticals LLC | — | — | Cash or cash equivalent | $172,650.00 | Research |
| Study: BIMATOPROST | ||||||
| 06/19/2024 | Oyster Point Pharma, Inc. | TYRVAYA (Drug), Ryzumvi | Food and Beverage | In-kind items and services | $19.99 | General |
| Category: Dry eyes | ||||||
| 06/05/2024 | Glaukos Corporation | — | Food and Beverage | Cash or cash equivalent | $27.81 | General |
| 04/19/2024 | Alcon Research LLC | — | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| 04/17/2024 | Glaukos Corporation | — | Food and Beverage | Cash or cash equivalent | $30.75 | General |
| 03/22/2024 | Oyster Point Pharma, Inc. | TYRVAYA (Drug), PHENTOLAMINE MESYLATE | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| Category: Dry eyes | ||||||
| 03/18/2024 | Glaukos Corporation | — | Food and Beverage | Cash or cash equivalent | $37.42 | General |
| 01/29/2024 | Glaukos Corporation | — | Food and Beverage | Cash or cash equivalent | $34.78 | General |
| 12/18/2023 | Glaukos Corporation | — | Food and Beverage | Cash or cash equivalent | $24.75 | General |
| 06/01/2023 | Kowa Research Institute, Inc. | — | Food and Beverage | Cash or cash equivalent | $100.00 | General |
| 10/19/2022 | Allergan, Inc. | BOTOX (Biological) | Consulting Fee | Cash or cash equivalent | $975.00 | General |
| Category: FACIAL AESTHETICS | ||||||
| 04/27/2022 | GLAUKOS CORPORATION | — | Food and Beverage | Cash or cash equivalent | $28.74 | General |
| 02/21/2022 | Horizon Therapeutics plc | TEPEZZA (Drug) | Food and Beverage | In-kind items and services | $24.01 | General |
| Category: TEPEZZA | ||||||
| 01/20/2022 | Allergan, Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $21.56 | General |
| Category: FACIAL AESTHETICS | ||||||
| 01/11/2022 | GLAUKOS CORPORATION | — | Food and Beverage | Cash or cash equivalent | $20.69 | General |
| 12/22/2021 | Glaukos Corporation | — | Food and Beverage | In-kind items and services | $15.87 | General |
| 12/17/2021 | Bausch Health US, LLC | — | — | Cash or cash equivalent | $5,346.00 | Research |
| Study: A Phase 3, Multi-Center, Open-Label, Single-Arm Extension Clinical Trial to Assess the Extended Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects who Completed Trial NVU-003 (SEECASE-2 OLE) | ||||||
| 12/14/2021 | Aerie Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| 11/23/2021 | Bausch Health US, LLC | — | — | Cash or cash equivalent | $5,346.00 | Research |
| Study: A Phase 3, Multi-Center, Open-Label, Single-Arm Extension Clinical Trial to Assess the Extended Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects who Completed Trial NVU-003 (SEECASE-2 OLE) | ||||||
| 11/15/2021 | Dompe US, Inc. | — | Honoraria | Cash or cash equivalent | $2,400.00 | General |
| 10/28/2021 | Allergan, Inc. | — | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| 10/20/2021 | Bausch Health US, LLC | — | — | Cash or cash equivalent | $6,502.50 | Research |
| Study: A Phase 3, Multi-Center, Open-Label, Single-Arm Extension Clinical Trial to Assess the Extended Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects who Completed Trial NVU-003 (SEECASE-2 OLE) | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3, Multi-Center, Randomized, Double- Masked, Saline-Controlled Trial to Evaluate the Effect of NOV03 (Perfluorohexyloctane) on Signs and Symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction (GOBI) | Bausch Health US, LLC | $316,090 | 6 |
| Initial Qualitative Study of a Prototype OCT+Aberrometry Device (All in One Cataract Diagnostics) | Alcon Research LLC | $198,579 | 234 |
| BIMATOPROST | Amneal Pharmaceuticals LLC | $172,650 | 1 |
| A Phase 3, Multi-Center, Open-Label, Single-Arm Extension Clinical Trial to Assess the Extended Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects who Completed Trial NVU-003 (SEECASE-2 OLE) | Bausch Health US, LLC | $89,071 | 17 |
| Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease | Kala Pharmaceuticals, Inc. | $50,800 | 4 |
| A STUDY OF THE CONCURRENT USE OF AGN-190584 AND AGN-199201 IN PARTICIPANTS WITH PRESBYOPIA | Allergan Inc. | $12,490 | 1 |
| AGN-199201 FOR THE TREATMENT OF ERYTHEMA WITH ROSACEA | Allergan Inc. | $5,000 | 1 |
| TOPICAL OPHTHALMIC AGN-195263 FOR THE TREATMENT OF EVAPORATIVE DRY EYE | Allergan Inc. | $4,004 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $2,527 | 6 |
| 24-hr Intraocular pressure control with Brinzolamide 1% / Brimonidine 0.2% ophthalmic suspension vs. vehicle. | Alcon Research Ltd | $2,486 | 1 |
| A PHASE 2B3, MULTICENTER, DOSE-RANGING, RANDOMIZED, DOUBLE-MASKED, PLACEBOCONTROLLED STUDY OF XAF5 OINTMENT FOR REDUCTION OF LOWER LID STEATOBLEPHARON | Allergan Inc. | $234.86 | 1 |
| A multicenter, open-label, single arm study in patients with open angle glaucoma or ocular hypertension who have not had previous laser trabeculoplasty treatment | Allergan Inc. | $16.20 | 2 |
About Dr. David Wirta, MD
Dr. David Wirta, MD is a Ophthalmology healthcare provider based in Newport Beach, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1255435822.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Wirta, MD has received a total of $890,793 in payments from pharmaceutical and medical device companies, with $184,101 received in 2024. These payments were reported across 310 transactions from 20 companies. The most common payment nature is "" ($853,948).
Ad
Practice Information
- Specialty Ophthalmology
- Location Newport Beach, CA
- Active Since 09/12/2006
- Last Updated 12/18/2023
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1255435822
Products in Payments
- ACTHAR (Biological) $5,850
- Humphrey HFA (Device) $5,000
- SIMBRINZA (Biological) $2,527
- Simbrinza (Drug) $2,486
- TYRVAYA (Drug) $1,820
- BOTOX (Biological) $996.56
- TearCare (Device) $89.53
- XIIDRA (Drug) $37.38
- RESTASIS MULTIDOSE (Drug) $24.82
- TEPEZZA (Drug) $24.01
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Newport Beach
Dr. Sheri Rowen, Md, MD
Ophthalmology — Payments: $1.0M
Ophthalmology $1.0M
Dr. Ehsan Sadri, M.d, M.D
Ophthalmology — Payments: $413,628
Ophthalmology $413,628
Alena Reznik, M.d, M.D
Ophthalmology — Payments: $122,470
Ophthalmology $122,470
Arlene Gwon, Md, MD
Ophthalmology — Payments: $86,643
Ophthalmology $86,643
Dr. Jacob Reznik, M.d, M.D
Ophthalmology — Payments: $42,236
Ophthalmology $42,236
Gregg Feinerman, M.d, M.D
Ophthalmology — Payments: $24,786
Ophthalmology $24,786